ReviewCurrent cancer drug targets2026
Cancer Vaccines: Mechanisms, Clinical Applications, Challenges, and Future Directions in Precision Medicine.
Review in Current cancer drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer poses a major health burden worldwide, necessitating the development of novel therapeutic approaches. Personalized cancer vaccines represent a promising form of immunotherapy that enhances the ability of the immune system to recognize and destroy tumor cells through tumor-associated and cancer-specific antigens. This review categorizes cancer vaccines into preventive, therapeutic, and personalized vaccines, discussing their mechanisms, clinical applications, and current FDA-approved examples, such as Sipuleucel-T and HPV vaccines. We highlight the recent advances in RNA-based vaccines, viral vectors, and nanotechnology, along with the synergistic role of cancer vaccines and immune checkpoint inhibitors in improving therapeutic efficacy. Overcoming ethical, regulatory, and technological barriers through global collaboration is essential for maximizing vaccine efficacy and enhancing patient outcomes. This review highlights the pivotal role of personalized vaccines in advancing precision medicine and reshaping cancer treatment paradigms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.